Creative Medical Technology Holdings, Inc. Amortization of Debt Issuance Costs
Creative Medical Technology Holdings, Inc. (CELZ) reported Amortization of Debt Issuance Costs of $132.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2019-04-01
- Creative Medical Technology Holdings, Inc. amortization of debt issuance costs for the quarter ending 2018-12-31 was $130.14K.
- Creative Medical Technology Holdings, Inc. amortization of debt issuance costs for fiscal 2018 was $132.00K, a 9938.02% increase from fiscal 2017.
- Creative Medical Technology Holdings, Inc. amortization of debt issuance costs for fiscal 2017 was $1.31K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2018-12-31 | $130.14K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $132.00K 10-K · filed 2019-04-01 | |
| 2018-09-30 | $1.86K 10-Q · filed 2018-11-14 | ||
| 2017-12-31 | $1.31K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |